Norges Bank bought a new position in Cencora, Inc. (NYSE:COR – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,435,250 shares of the company’s stock, valued at approximately $822,506,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vestcor Inc lifted its position in Cencora by 0.5% during the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after purchasing an additional 28 shares in the last quarter. JFS Wealth Advisors LLC lifted its position in Cencora by 30.2% during the fourth quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after purchasing an additional 29 shares in the last quarter. Apollon Wealth Management LLC lifted its position in Cencora by 0.5% during the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after purchasing an additional 30 shares in the last quarter. Accent Capital Management LLC lifted its position in Cencora by 36.1% during the fourth quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock valued at $38,000 after purchasing an additional 30 shares in the last quarter. Finally, CYBER HORNET ETFs LLC lifted its position in Cencora by 6.8% during the fourth quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock valued at $164,000 after purchasing an additional 31 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.
Cencora Price Performance
Shares of Cencora stock opened at $269.21 on Friday. The stock’s 50-day simple moving average is $298.56 and its 200-day simple moving average is $333.91. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a market capitalization of $52.38 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 1.24 and a beta of 0.64. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.
Cencora Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s payout ratio is currently 18.40%.
Cencora announced that its board has approved a share repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on COR. Evercore set a $360.00 target price on Cencora in a research report on Wednesday, April 8th. Wells Fargo & Company lowered their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. UBS Group lifted their target price on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Finally, Citigroup lowered their target price on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.
Check Out Our Latest Analysis on COR
Cencora Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Articles
- Five stocks we like better than Cencora
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
